Show simple item record

dc.contributor.authorFerguson, P
dc.contributor.authorHills, R
dc.contributor.authorGrech, A
dc.contributor.authorBetteridge, S
dc.contributor.authorKjeldsen, L
dc.contributor.authorDennis, Michael
dc.contributor.authorVyas, P
dc.contributor.authorGoldstone, Anthony H
dc.contributor.authorMilligan, D
dc.contributor.authorClark, R
dc.contributor.authorRussell, N
dc.contributor.authorCraddock, C
dc.date.accessioned2016-09-06T09:26:40Z
dc.date.available2016-09-06T09:26:40Z
dc.date.issued2016-08-18
dc.identifier.citationAn operational definition of primary refractory acute myeloid leukaemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation. 2016: Haematologicaen
dc.identifier.issn1592-8721
dc.identifier.pmid27540133
dc.identifier.doi10.3324/haematol.2016.148825
dc.identifier.urihttp://hdl.handle.net/10541/619851
dc.description.abstractUp to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have the optimal treatment modalities been defined. We studied 8907 patients with newly diagnosed acute myeloid leukemia and examined outcomes in patients with refractory disease defined using differing criteria which have previously been proposed. These included failure to achieve complete remission after one cycle of induction chemotherapy (RES), less than a 50% reduction in blast numbers with >15% residual blasts after one cycle of induction chemotherapy (REF1 ) and failure to achieve complete remission after two courses of induction chemotherapy (REF2). 5 year overall survival was decreased in patients fulfilling any criteria for refractory disease compared with patients achieving a complete remission after one cycle of induction chemotherapy: 9% and 8% in patients with REF1 and REF 2 versus 40% (p <0.0001). Allogeneic stem cell transplantation improved survival in the REF1 (HR 0.58 (0.46-0.74), p=0.00001) and REF2 (HR 0.55 (0.41-0.74), p=0.0001) cohorts. Utilization of REF1 criteria permits the early identification of patients whose outcome after one course of induction chemotherapy is very poor and informs a novel definition of primary refractory acute myeloid leukemia. Furthermore, these data demonstrate that allogeneic stem cell transplantation represents an effective therapeutic modality in selected patients with primary refractory acute myeloid leukaemia.
dc.languageENG
dc.language.isoenen
dc.rightsArchived with thanks to Haematologicaen
dc.titleAn operational definition of primary refractory acute myeloid leukaemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.en
dc.typeArticleen
dc.contributor.departmentQueen Elizabeth Hospital, Birminghamen
dc.identifier.journalHaematologicaen
html.description.abstractUp to 30% of adults with acute myeloid leukemia fail to achieve a complete remission after induction chemotherapy - termed primary refractory acute myeloid leukemia. There is no universally agreed definition of primary refractory disease, nor have the optimal treatment modalities been defined. We studied 8907 patients with newly diagnosed acute myeloid leukemia and examined outcomes in patients with refractory disease defined using differing criteria which have previously been proposed. These included failure to achieve complete remission after one cycle of induction chemotherapy (RES), less than a 50% reduction in blast numbers with >15% residual blasts after one cycle of induction chemotherapy (REF1 ) and failure to achieve complete remission after two courses of induction chemotherapy (REF2). 5 year overall survival was decreased in patients fulfilling any criteria for refractory disease compared with patients achieving a complete remission after one cycle of induction chemotherapy: 9% and 8% in patients with REF1 and REF 2 versus 40% (p <0.0001). Allogeneic stem cell transplantation improved survival in the REF1 (HR 0.58 (0.46-0.74), p=0.00001) and REF2 (HR 0.55 (0.41-0.74), p=0.0001) cohorts. Utilization of REF1 criteria permits the early identification of patients whose outcome after one course of induction chemotherapy is very poor and informs a novel definition of primary refractory acute myeloid leukemia. Furthermore, these data demonstrate that allogeneic stem cell transplantation represents an effective therapeutic modality in selected patients with primary refractory acute myeloid leukaemia.


This item appears in the following Collection(s)

Show simple item record